Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

被引：2
|
作者：
Kambhampati, Suman [1 ]
McMahon, Christine M. [2 ]
Eghtedar, Alireza [3 ]
Pollyea, Daniel A. [2 ]
de Botton, Stephane [4 ,5 ]
Pigneux, Arnaud [6 ]
Cherry, Mohamad [7 ]
Ball, Brian J. [8 ]
Borthakur, Gautam [9 ]
Cluzeau, Thomas [10 ]
Schiller, Gary J. [11 ]
Hu, Beibei [12 ]
Volkert, Angela [12 ]
Gausman, Joanie Aasen [12 ]
Hodgson, Graeme [12 ]
Roth, David A. [12 ]
Warlick, Erica D. [12 ]
Kelly, Michael J. [12 ]
Stein, Eytan [13 ]
机构：
[1] HCA Midwest Hlth, Sarah Cannon Canc Inst, Res Med Ctr, Kansas City, MO USA
[2] Univ Colorado, Sch Med, Div Hematol, Anschutz Med Campus, Aurora, CO USA
[3] St Lukes Med Ctr, Colorado Blood Canc Inst Presbyterian, Denver, CO USA
[4] Gustave Roussy, Dept Hematol, Villejuif, France
[5] Gustave Roussy, Dept Innovat Therapeut, Villejuif, France
[6] CHU Bordeaux, Hop Haut Levegue, Bordeaux, France
[7] Carol Simon Canc Ctr, Atlantic Hlth Syst, Morristown, NJ USA
[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[10] Ctr Hosp Univ Nice, Clin Hematol Dept, Nice, France
[11] UCLA, David Geffen Sch Med, Los Angeles, CA 90095 USA
[12] Syros Pharmaceut Inc, Cambridge, MA USA
[13] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-156564
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3333 / 3335
页数：3
相关论文
共 50 条
  • [1] SELECT-AML-1 Trial in Progress: A Phase 2 Study of Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-Positive AML who are Ineligible for Standard Induction Therapy
    Kambhampati, Suman
    Eghtedar, Alireza
    McMahon, Christine
    De Botton, Stephane
    Pigneux, Arnaud
    Ball, Brian
    Borthakur, Gautam
    Angela, Volkert
    Gausman, Joanie Aasen
    Kristen, Baker
    Hodgson, Graeme
    Warlick, Erica
    Roth, David
    Kelly, Michael
    Pollyea, Daniel
    Stein, Eytan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S213 - S213
  • [2] Tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy (SELECT AML-1).
    Stein, Eytan
    De Botton, Stephane
    Pigneux, Arnaud
    McMahon, Christine
    Ball, Brian
    Borthakur, Gautam
    Eghtedar, Alireza
    Kambhampati, Suman
    Tache, Jason
    Wang, Eunice S.
    Kelley, Heather
    Volkert, Angela
    Baker, Kristen
    Kang-Fortner, Qing
    Madigan, Catherine
    Warlick, Erica D.
    Roth, David A.
    Kell, Michael
    Pollyea, Daniel Aaron
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy
    Borate, Uma
    McMahon, Christine
    Fenaux, Pierre
    Heiblig, Mael
    Peterlin, Pierre
    Ball, Brian
    Chantepie, Sylvain
    Eghtedar, Alireza
    Kambhampati, Suman
    Solh, Melhem
    Torregrosa-Diaz, Jose
    Braun, Thorsten
    de Botton, Stephan
    Dugan, James
    Feld, Jonathan
    Gourin, Marie-Pierre
    Pigneux, Arnaud
    Robin, Jean-Baptiste
    Schiller, Gary
    Stein, Eytan
    Roth, David
    Baker, Kristen
    Paul, Sofia
    Kelly, Michael
    Pollyea, Daniel
    Cluzeau, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S307 - S307
  • [4] A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results
    Pratz, Keith W.
    Cherry, Mohamad
    Altman, Jessica K.
    Cooper, Brenda W.
    Cruz, Jose Carlos
    Jurcic, Joseph G.
    Levis, Mark
    Lin, Tara
    Perl, Alexander E.
    Podoltsev, Nikolai A.
    Schiller, Gary J.
    Hill, Jason E.
    James, Angela
    Lu, Qiaoyang
    Tiu, Ramon V.
    BLOOD, 2020, 136
  • [5] CULMINATE: A phase II study of cusatuzumab plus azacitidine in patients with newly diagnosed AML, ineligible for intensive chemotherapy.
    Trudel, Geralyn Carol
    Howes, Angela J.
    Jeste, Neelum
    Tryon, Jeffrey J.
    Xiu, Liang
    Kane, Colleen
    Nottage, Kerri
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia
    Sawa, Masashi
    Miyamoto, Toshihiro
    Kim, Hee-Je
    Hiramatsu, Yasushi
    Cheong, June-Won
    Ikezoe, Takayuki
    Naoe, Tomoki
    Akashi, Koichi
    Morita, Satoshi
    Kosako, Masanori
    Ikegaya, Moyu
    Terada, Wataru
    Kadokura, Takeshi
    Hill, Jason
    Miyawaki, Shuichi
    Gill, Stanley C.
    Heinloth, Alexandra
    Hasabou, Nahla
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (01) : 56 - 67
  • [7] Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
    Perez, Jorge M. Ramos
    Tinajero, Jose
    Ngo, Dat
    Zhang, Jianying
    Koller, Paul B.
    Agrawal, Vaibhav
    Pourhassan, Hoda
    Al Malki, Monzr M.
    Salhotra, Amandeep
    Ali, Haris
    Aribi, Ahmed
    Sandhu, Karamjeet S.
    Arslan, Shukaib
    Otoukesh, Salman
    Amanam, Idoroenyi
    Artz, Andrew S.
    Becker, Pamela S.
    Stewart, Forrest M.
    Smith, Eileen P.
    Curtin, Peter
    Forman, Stephen J.
    Nakamura, Ryotaro
    Pullarkat, Vinod A.
    Marcucci, Guido
    Stein, Anthony S.
    Aldoss, Ibrahim
    Ball, Brian J.
    BLOOD, 2022, 140 : 9039 - 9040
  • [8] SELECT-MDS-1 Trial in Progress: A Phase 3 Randomized, DoubleBlind, Placebo-Controlled Study of Tamibarotene/Azacitidine Versus Placebo/Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-Positive Higher-Risk MDS
    DeZern, Amy
    Fenaux, Pierre
    Deeren, Dries
    Campelo, Maria Diez
    Luebbert, Michael
    Krishnamurthy, Pramila
    Nagy, Zsolt
    Basak, Grzegorz
    Jonasova, Anna
    Geissler, Klaus
    Ofran, Yishai
    Volkert, Angela
    Baker, Kristen
    Chisholm, Jaime
    Kang-Fortner, Qing
    Roth, David A.
    Kelly, Michael
    Marconi, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S303 - S304
  • [9] A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy
    Nannis, Gabriel N.
    Griffiths, Elizabeth A.
    Savona, Michael R.
    Odenike, Olatoyosi
    Roboz, Gail J.
    O'Connell, Casey L.
    Dillingham, Jacqueline
    Wason, Prieya
    Zhu, Lixia
    Chan, Danna
    Keer, Harold N.
    Oganesian, Aram
    Dao, Kim-Hien
    DiNardo, Courtney D.
    BLOOD, 2021, 138
  • [10] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
    Short, Nicholas J.
    Sedarati, Farhad
    Zhao, Dan
    Tsukurov, Olga
    Friedlander, Sharon
    Faller, Douglas V.
    BLOOD, 2020, 136
12345